Table 2.
Crude- and multivariable-adjusted hazard ratios for cardiovascular disease according to treatment modality in prostate cancer cohort
| Treatment group | N | Event | Person year | Incidence | H.R (95% Confidence interval) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Crude | Adjusted* | ||||||||
| IHD | No medication | 1169 | 84 | 7128.83 | 11.78 | 1 | Ref. | Ref. | |
| GnRH agonists | 548 | 39 | 2723.23 | 14.32 | 1.257 | (0.858-1.840) | 1.107 | (0.743-1.651) | |
| Antiandrogen only | 138 | 9 | 536.26 | 16.78 | 1.54 | (0.774-3.067) | 1.337 | (0.661-2.706) | |
| AMI | No medication | 1431 | 29 | 8865.31 | 3.27 | 1 | Ref. | Ref. | |
| GnRH agonists | 709 | 23 | 3549.95 | 6.48 | 1.996 | (1.151-3.461) | 1.503 | (0.841-2.688) | |
| Antiandrogen only | 166 | 4 | 681.74 | 5.87 | 1.799 | (0.631-5.127) | 1.208 | (0.413-3.529) | |
* Adjusted for all covariated in Table 1